About ALIQUANTUMRX INC
AliquantumRx is a near-clinical entry company focused on developing Cethromycin HCl, a short-course oral therapy for eliminating dormant liver-stage malaria and preventing relapse. The company has received over $6M in non-dilutive funding for IND-enabling studies and early clinical development.
Development of Cethromycin HCl for liver-stage malaria treatmentExecution of regulatory path toward human proof-of-conceptUtilization of prior human safety data from over 5,000 subjects
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ALIQUANTUMRX INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.